Portola expands collaboration with Daiichi to develop AndexXa in Germany
Portola Pharmaceuticals (PTLA) has expanded its existing clinical collaboration agreement with Daiichi Sankyo to develop AndexXa (andexanet alfa) as an antidote for the former’s Factor Xa inhibitor named as edoxaban.
AndexXa is currently under EMA review for reversal of Factor Xa inhibition in patients experiencing a life-threatening or uncontrolled bleed and for patients requiring urgent or emergency surgery. As part of the updated agreement, Portola will expand the ongoing ANNEXA-4 study in bleeding patients in Germany.
